Relevium Technologies Inc.'s securities will resume trading as it has provided certain clarifications to the TSX Venture Exchange.

The exchange previously instructed Relevium to halt trading in its common shares in order to provide certain documents relating to its proposed acquisition of the assets of BioGanix Ltd. for $4.3 million.

Relevium will resume trading on the TSX Venture Exchange at the market opening Jan 26.

The proposed acquisition of BioGanix represents a fundamental or significant transaction and as such it is subject to the approval by the TSX Venture Exchange. The company remains engaged in the process with the exchange and is working diligently in cooperation with the vendor and external consultants to ensure the fluidity of this transaction.

BioGanix is a Houston-based, privately held nutraceutical company focused on products related to brain, heart and digestive health, as well as joint support, sold online.